Clinical Trials Browser

Phase 2/3 × NETWORK × Cetuximab × Clear all

NCT02438722 2026-05-18

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Phase 2/3 Completed

174 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung